TW202319400A - 用於治療aml之抗體 - Google Patents

用於治療aml之抗體 Download PDF

Info

Publication number
TW202319400A
TW202319400A TW111133446A TW111133446A TW202319400A TW 202319400 A TW202319400 A TW 202319400A TW 111133446 A TW111133446 A TW 111133446A TW 111133446 A TW111133446 A TW 111133446A TW 202319400 A TW202319400 A TW 202319400A
Authority
TW
Taiwan
Prior art keywords
antibody
cells
seq
cdr
acid sequence
Prior art date
Application number
TW111133446A
Other languages
English (en)
Chinese (zh)
Inventor
瑪麗亞 阿曼
羅琳 波斯
克里斯多福 波伊茲克
馬汀 衛瑟
泰瑞莎 柯爾本
珍 埃克曼
麥爾斯 卡拉尼可斯
狄 梅迪洛斯 布魯諾 卡尼洛
Original Assignee
瑞士商赫孚孟拉羅股份公司
美商建南德克公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司, 美商建南德克公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW202319400A publication Critical patent/TW202319400A/zh

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/804—Blood cells [leukemia, lymphoma]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
TW111133446A 2021-09-02 2022-09-02 用於治療aml之抗體 TW202319400A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202163240342P 2021-09-02 2021-09-02
US63/240,342 2021-09-02

Publications (1)

Publication Number Publication Date
TW202319400A true TW202319400A (zh) 2023-05-16

Family

ID=83438540

Family Applications (1)

Application Number Title Priority Date Filing Date
TW111133446A TW202319400A (zh) 2021-09-02 2022-09-02 用於治療aml之抗體

Country Status (6)

Country Link
US (1) US20240352136A1 (enExample)
EP (1) EP4396230A1 (enExample)
JP (1) JP2024533119A (enExample)
CN (1) CN117916266A (enExample)
TW (1) TW202319400A (enExample)
WO (1) WO2023031403A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2024279278A1 (en) 2023-05-31 2025-12-18 Capstan Therapeutics, Inc. Lipid nanoparticle formulations and compositions
US20250127728A1 (en) 2023-10-05 2025-04-24 Capstan Therapeutics, Inc. Constrained Ionizable Cationic Lipids and Lipid Nanoparticles
WO2025076113A1 (en) 2023-10-05 2025-04-10 Capstan Therapeutics, Inc. Ionizable cationic lipids with conserved spacing and lipid nanoparticles
US20250302763A1 (en) 2024-02-22 2025-10-02 Capstan Therapeutics, Inc. Immune engineering amplification
WO2025217452A1 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Constrained ionizable cationic lipids and lipid nanoparticles
WO2025217454A2 (en) 2024-04-11 2025-10-16 Capstan Therapeutics, Inc. Ionizable cationic lipids and lipid nanoparticles

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2480671B8 (en) 2009-09-22 2015-10-28 ProBioGen AG Process for producing molecules containing specialized glycan structures
GB201507827D0 (en) * 2015-05-07 2015-06-17 Adc Therapeutics Sarl Diagnostic test
KR20190017735A (ko) 2016-04-07 2019-02-20 캔써 리서치 테크놀로지 리미티드 종양 특이적 세포 고갈을 위한 항 cd25 fc 감마 수용체 이중특이적 항체
US11879014B2 (en) 2017-03-17 2024-01-23 Tusk Therapeutics Ltd. Method of treating cancer or depleting regulatory T cells in a subject by administering a human IGG1 anti-CD25 antibody
EP3649153B8 (en) 2017-07-06 2025-07-16 Tusk Therapeutics Ltd Fc optimised anti-cd25 antibodies for tumor specific cell depletion
KR102097449B1 (ko) 2017-07-17 2020-04-06 성균관대학교산학협력단 복수의 층간 인터락킹 구조를 포함하는 건식 접착 시스템
KR101930470B1 (ko) 2017-07-20 2019-03-14 (주)파트론 지문 센서 패키지
KR102570856B1 (ko) 2017-07-21 2023-08-25 상라오 징코 솔라 테크놀러지 디벨롭먼트 컴퍼니, 리미티드 페로브스카이트 태양전지 및 이를 포함하는 탬덤 태양전지
KR20190069030A (ko) 2017-12-11 2019-06-19 삼성전자주식회사 디스플레이 장치 및 그 제어 방법
US10752691B2 (en) 2018-03-13 2020-08-25 Tusk Therapeutics Ltd. Anti-CD25 antibody agents
TWI848030B (zh) * 2018-12-18 2024-07-11 比利時商阿根思公司 Ｃｄ７０組合治療
CN114302746A (zh) * 2019-06-10 2022-04-08 Adc治疗有限公司 包含抗cd25抗体药物缀合物和另一剂的组合疗法

Also Published As

Publication number Publication date
JP2024533119A (ja) 2024-09-12
US20240352136A1 (en) 2024-10-24
EP4396230A1 (en) 2024-07-10
WO2023031403A1 (en) 2023-03-09
CN117916266A (zh) 2024-04-19

Similar Documents

Publication Publication Date Title
US12209128B2 (en) Anti-PD-L1 antibodies
JP6496349B2 (ja) ヒト及び非ヒトｃｄ３に結合可能なｃｄ３結合分子
US20260098089A1 (en) Antagonist anti-cd7 antibodies
CN107530428B (zh) Icos的抗体
US20240352136A1 (en) Antibodies for the treatment of aml
EP3378487B1 (en) Combination therapy using t cell redirection antigen binding molecule against cell having immunosuppressing function
AU2012245477B2 (en) Antibodies and other molecules that bind B7-H1 and PD-1
KR102703605B1 (ko) 항-mct1 항체 및 그의 용도
US20190330351A1 (en) Anti-pd-l1 antibodies
US20260049143A1 (en) Multispecific antibody with combination therapy for immuno-oncology
BR112020016501A2 (pt) anticorpo ou fragmento de ligação a antígeno do mesmo, anticorpo ou um fragmento de ligação a antígeno que se ligam especificamente a um epótipo de cd25 humano, variante amadurecida por afinidade de um anticorpo ou seu fragmento de ligação a antígeno, molécula de ácido nucleico, vetor de ácido nucleico, célula hospedeira, método para produzir um anticorpo ou fragmento de ligação a antígeno do mesmo, composição farmacêutica, uso de um anticorpo ou fragmento de ligação a antígeno do mesmo, método para tratar câncer em um indivíduo, método para esgotar células t reguladoras em um tumor em um indivíduo, anticorpo ou fragmento de ligação a antígeno que compete com um anticorpo, kit, método para preparar um anticorpo anti-cd25 e método para preparar uma composição farmacêutica
KR20190130137A (ko) 종양 특이적 세포 고갈을 위한 fc-최적화된 항-cd25
JP2018522541A (ja) 抗ｃｌｌ−１抗体及び使用方法
CN110392694A (zh) 针对pd-1的抗体及其用途
US20240101667A1 (en) Methods for identifying lilrb-blocking antibodies
TW202116807A (zh) 用於治療特定患者之癌症的抗體組合
JP2023536631A (ja) 多重特異性結合性作用剤およびその使用
US20250313631A1 (en) Treatment and prevention of cancer using vista antigen-binding molecules
HK40104576A (zh) 用於治疗aml的抗体
RU2855103C1 (ru) Молекулы антитела к LILRB3 и их применение
US20240190965A1 (en) Targeting anti-human pd 1h/vista to treat hematologic disorders
RU2829587C2 (ru) Новые молекулы антагонистических анти-tnfr2-антител
IL323711A (en) Multispecific binding agents against PD-L1 and CD137 for cancer treatment
HK40000917A (en) Pd-l1-specific antibodies and methods of using the same
HK1193991B (en) Antibodies and other molecules that bind b7-h1 and pd-1